Borderline Medical Device Determination Tool

A borderline product is one that does not easily fit into a single regulatory category because its characteristics, intended purpose, or mechanism of action sit at the crossroads of multiple legal frameworks. These products typically blur the lines between the Medical Device Regulation (MDR) or In Vitro Diagnostic Regulation (IVDR) and companion frameworks—such as medicinal products, biocides, cosmetics, personal protective equipment (PPE), or general consumer goods. Determining the exact qualification is a critical first step to avoid severe market enforcement penalties or wasting capital on unnecessary compliance protocols.

The distinction is fundamentally determined by the product's principal mode of action, which must be supported by robust scientific evidence. To qualify as a medical device, the primary intended effect in or on the human body must be achieved through physical, structural, or mechanical means (e.g., anatomical barriers, fluid irrigation, or support matrices). If the primary effect is achieved via pharmacological, immunological, or metabolic pathways (such as chemical interactions with cellular receptors or target antibody bindings), the product is regulated as a medicinal product under Directive 2001/83/EC.

Under MDR Annex VIII, Rule 14, if a physical device incorporates a companion substance that, if used separately, would be considered a medicinal product, it triggers an automatic Class III classification if that substance has an action ancillary to the device. For example, root canal irrigation solutions that mechanically rinse debris but rely on chemical properties (like chlorhexidine) to disinfect fall into this category. The MDCG Borderline Manual establishes that omitting an antimicrobial claim from your labelling is legally immaterial if the substance naturally exerts a secondary chemical effect under objective scientific scrutiny.

The critical differentiator is the primary target of application and intent of protection. Medical devices act directly on an individual patient or protect a specific localized patient treatment space to intercept disease transmission. In contrast, products falling under the Biocidal Products Regulation (BPR) are intended to globally treat inanimate environments, surfaces, or general textiles (such as a long-term antibacterial coating applied to industrial fabrics). Because they treat an environmental object rather than a specific patient, they are excluded from the MDR.

Qualification depends entirely on who the product is explicitly designed to safeguard. If a protective asset is engineered to protect the safety and health of the patient (such as an examination table cover preventing patient cross-contamination), it qualifies as a medical device. However, if the product is designed solely to shield the healthcare professional or caregiver from the environment—such as a rigid Plexiglas intubation shield box built to trap airborne droplets during surgery—it is classified as Personal Protective Equipment (PPE) and falls outside the scope of the MDR.

The Helsinki Procedure is an administrative consulting framework that allows EU Member State competent authorities to exchange scientific data and develop a unified consensus when a product's classification is disputed. These consensus decisions are compiled into the MDCG Borderline Manual. While the manual provides highly authoritative guidance reflecting the agreed position of European regulators, it is not legally binding. Statutory qualification decisions are ultimately determined case-by-case by national competent authorities in their respective jurisdictions, or authoritatively by the Court of Justice of the European Union.